Evidence map›Paper›PMID 41812664›Full record

ArticleCell reports. Medicine2026

Detection of mitochondrial DNA mutations in T cells following 5-FU or cisplatin exposure.

Catherine Kirkpatrick, Charles M Quick, Steven R Post, Yuet-Kin Leung, Ruud P M Dings, Chrystal M Paulos, Lyle Burdine, Yong-Chen William Lu

Abstract read
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Catherine KirkpatrickDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA; Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR 72205, USA.
Charles M QuickDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA.
Steven R PostDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA; Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR 72205, USA.
Yuet-Kin LeungDepartment of Pharmacology and Toxicology, College of Medicine, UAMS, Little Rock, AR 72205, USA.
Ruud P M DingsDepartment of Radiation Oncology, College of Medicine, UAMS, Little Rock, AR 72205, USA.
Chrystal M PaulosDepartment of Surgery and Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA.
Lyle BurdineDepartment of Surgery, College of Medicine, UAMS, Little Rock, AR 72205, USA.
Yong-Chen William LuDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA; Winthrop P. Rockefeller Cancer Institute, UAMS, Little Rock, AR 72205, USA. Electronic address: ylu@uams.edu.

Funding

Expanding Translational Research in ArkansasUL1TR003107 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI JAMES, LAURA P · 2019 to 2023
$21.6M
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-RenewalR01CA143130 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI NAKAGAWA, MAYUMI · 2010 to 2025
$10.0M
Institutional Career DevelopmentKL2TR003108 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI ARTHUR, JOHN M., BORSHEIM, ELISABET · 2019 to 2023
$2.3M
Improvement of cellular immunotherapy during dysbiosis- ResubmissionR01CA245083 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI DINGS, RUUD P.M. · 2021 to 2025
$1.9M
NCATS NIH HHS KL2 TR003108NCATS NIH HHS UL1 TR003107NCI NIH HHS R01 CA143130NCI NIH HHS R01 CA245083
6 · The paper itself

Abstract

T cells are pivotal to cancer immunotherapy, yet chemotherapy may erode their fitness. Using a single-cell technique, we show that exposure to two widely used chemotherapeutic agents, 5-FU (5-fluorouracil) and cisplatin, induces non-synonymous mitochondrial DNA (mtDNA) mutations in T cells. Notably, nearly all detected mtDNA mutations are transition mutations. Like the effects observed in genomic DNA mutations, the impacts of mtDNA mutations in T cells appear to be random. Some T cells with mtDNA mutations concentrate in clusters associated with gene markers, while others do not. Additionally, several mtDNA mutations are found in the fraction of treated T cells with low mitochondrial activity, suggesting their potential effect on mitochondrial function. Importantly, mtDNA mutations are detected in tumor-infiltrating T cells from patients with colorectal cancer who received chemotherapy. Our findings uncover an unappreciated consequence of chemotherapy on T cell mitochondria, and these results raise concerns about administering immunotherapy and chemotherapy concurrently.

Indexed as

CisplatinDNA, MitochondrialFluorouracilMutationT-LymphocytesAntineoplastic AgentsColorectal NeoplasmsHumansMitochondriaAntineoplastic AgentsCisplatinDNA, MitochondrialFluorouracilcancer immunotherapycombination therapymitochondrial biologysingle-cell genomicsT cell biology

Identifiers

PMID41812664
PMCPMC13006443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.